Trisalus Life Sciences, Inc. (TLSI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 14, 2024, by Trisalus Life Sciences, Inc., a Delaware corporation and emerging growth company. The filing serves to announce the Company's financial results and provide a business update for the quarter ended September 30, 2024.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing references a press release (Exhibit 99.1) containing these details but does not reproduce the figures within the 8-K body text.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document indicates that the Company issued a press release regarding its Q3 2024 results, but the specific variances are not listed here.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference which contains the business update and financial results. The text explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are enumerated in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2024) for specific Q3 2024 revenue, net loss, and cash position figures.
- Verify the Company's liquidity status and runway given the lack of specific cash flow data in this summary.
- Confirm the status of the Warrants (TLSIW) with an exercise price of $11.50 per share.
- Check for any updated operational milestones or clinical trial progress mentioned in the full press release.